ArticleEuropean journal of nutrition2025
High doses of the galactooligosaccharides, 2'-fucosyllactose alleviate immunodeficiency in vitro and in vivo.
Article in European journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGalactooligosaccharides (GOS) are widely added to infant formula milk powder. One of these, 2'-fucosyllactose (2'-FL), has many potential applications. This study investigated the immunomodulatory effects of GOS and 2'-FL, alone or in combination, on RAW 264.7 cells, and their impacts on cyclophosphamide (CTX)-induced immunodeficiency in mice.
methodsWe used lipopolysaccharide (LPS)-treated RAW 264.7 cells and CTX-induced immunodeficient model mice to analyze the effects of GOS, 2'-FL, and the combination GOSFL on apparent indicators, cellular immunity, inflammation, intestinal barrier function, and the gut microbiota and its metabolites.
resultsIn vitro, GOS and 2'-FL promoted cell proliferation and nitric oxide production, and exhibited dose-dependent increases in the secretion of interleukin-10 (IL)-10, IL-6, and tumor necrosis factor-α. In vivo, high-dose administration GOS, 2'-FL, or GOSFL reduced the body weight and spleen index of immune-deficient mice, increased the number of splenic immune cells, alleviated inflammation, and promoted the expression of Occludin, ZO-1, and MUC2 to restore the intestinal mucosal barrier. GOS and 2'-FL each increased the relative abundances of Bacteroidota and Muribaculaceae, while decreasing those of Firmicutes, Lachnospiraceae, and Lactobacillaceae. Spearman correlation analysis revealed correlations between the gut microbiota and serum immune factors, as well as short-chain fatty acids.
conclusionGOS and 2'-FL significantly promoted cytokine secretion in vitro. High doses of GOS or 2'-FL in vivo reversed the adverse effects induced by CTX, modulated the gut microbiota, and boosted the immune response, with combination use producing similar effects.
Indexed as
Identifiers
40488907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.